CN1398635A - Piracetam medicine composition with function of promoting thinking and memory and its prepn - Google Patents
Piracetam medicine composition with function of promoting thinking and memory and its prepn Download PDFInfo
- Publication number
- CN1398635A CN1398635A CN 02123539 CN02123539A CN1398635A CN 1398635 A CN1398635 A CN 1398635A CN 02123539 CN02123539 CN 02123539 CN 02123539 A CN02123539 A CN 02123539A CN 1398635 A CN1398635 A CN 1398635A
- Authority
- CN
- China
- Prior art keywords
- piracetam
- function
- derivant
- injection
- thinking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229960004526 piracetam Drugs 0.000 title claims abstract description 52
- 230000006870 function Effects 0.000 title claims abstract description 18
- 230000001737 promoting effect Effects 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title abstract description 21
- 239000000203 mixture Substances 0.000 title abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 13
- 229960003180 glutathione Drugs 0.000 claims abstract description 11
- 230000002829 reductive effect Effects 0.000 claims abstract description 11
- 238000002347 injection Methods 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 26
- 241001597008 Nomeidae Species 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 15
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 13
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 13
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 235000003969 glutathione Nutrition 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000012047 saturated solution Substances 0.000 claims description 5
- 239000000890 drug combination Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 108010024636 Glutathione Proteins 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 238000005457 optimization Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000012856 packing Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 229910052694 Berkelium Inorganic materials 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- PWVKJRSRVJTHTR-UHFFFAOYSA-N berkelium atom Chemical compound [Bk] PWVKJRSRVJTHTR-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000718 radiation-protective agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is Piractetam medicine composition with the function of promoting thinking and memory and its preparation process. The composition consists of Piracetam and reductive glutathione in the weight ratio of 10-100 to 6-12 as well as pharmaceutically acceptable supplementary material. It has high curative effect, high stability, less adverse reaction and high safety.
Description
Technical field
The present invention relates to a kind of medicine, particularly relate to a kind of piracetam pharmaceutical composition and preparation method thereof with function of promoting thinking and memory with function of promoting thinking and memory.
Technical background
There are many deficiencies in existing piracetam medicine aspect component, dosage form and the production technology, the defective of the poor stability when making the piracetam medicine exist weak curative effect, not high, the untoward reaction side effect of stability to reach more greatly the hepatic and kidney function obstacle person used.
Summary of the invention
The objective of the invention is to overcome the above-mentioned shortcoming of prior art, a kind of good effect, stability is strong, the untoward reaction side effect is little and safety the is good piracetam pharmaceutical composition with function of promoting thinking and memory are provided; The present invention also aims to provide the preparation method of this invention medicine.
For achieving the above object, the piracetam pharmaceutical composition of the present invention with function of promoting thinking and memory contains following materials of weight proportions component:
Piracetam 10-100
Reduced glutathion 6-12
Other auxiliary material of acceptable on the pharmaceutics.
As optimization, its auxiliary material comprises alpha-cyclodextrin and derivant, beta-schardinger dextrin-and derivant thereof.
As optimization, its auxiliary material consumption be:
Alpha-cyclodextrin and derivant thereof are 1-5 times of the smooth molal quantity of pyrrole hila
Beta-schardinger dextrin-and derivant thereof are 1-5 times of the smooth molal quantity of pyrrole hila
As optimization, described alpha-cyclodextrin and derivant thereof and beta-schardinger dextrin-and derivant thereof can replace with gamma-cyclodextrin and derivant thereof.
As optimization, its auxiliary material also comprises sodium chloride for injection.
As optimization, the consumption of sodium chloride for injection is to account for 0.9% of solution total amount.
As optimization, its dosage form is small-volume injection, bulk capacity injection and lyophilized injectable powder, the water content of lyophilized injectable powder≤2%.
The piracetam preparation of drug combination method that the present invention has function of promoting thinking and memory comprises the following steps:
(1) piracetam is dissolved with water for injection, make saturated solution, under agitation be added drop-wise to again in the cyclodextrin aqueous solution, stir under the last lucifuge room temperature and further make piracetam cyclodextrin saturated solution.
(2) add sodium chloride solution and the reduced glutathion of handling through decolouring, stir, further this solution is filtered again.
As optimization, the mixing time of described (1) step is 3-5 hour; The filtration branch two-stage of described step (2) three times: the first order is the filter membrane of 0.45 μ m, and the second level is the filter membrane of 0.22 μ m, and be the membrane filtration with water for injection dilution back reuse 0.22 μ m the partial second time.
As optimization, the preparation method of lyophilized injectable powder also comprises carries out lyophilization to water content≤2% with above-mentioned medicinal liquid.
After adopting technique scheme, the indication of piracetam pharmaceutical composition of the present invention is:
(1) promotes reviving of coma patient after the neurosurgery;
(2) treatment oligophrenia.
Medicine of the present invention is compared with existing piracetam medicine, has following outstanding advantage:
(1) the crude drug inner quality standard is higher than national standard, has guaranteed the quality of the pharmaceutical preparations, has improved curative effect.
(2) by production technology of the present invention, make alpha-cyclodextrin and derivant thereof comprise the five-membered ring part of piracetam molecule, beta-schardinger dextrin-and derivant thereof comprise the amide groups part of piracetam molecule.Alpha-cyclodextrin and derivant thereof and β-Cyclodextrin and derivant thereof are worked in coordination with and are comprised the five no loop sections that the piracetam effect is better than only comprising with alpha-cyclodextrin and derivant thereof the piracetam molecule, the latter makes its amide groups exposed, is subject to light, heat, acid, alkali or other factor effects and decomposes; Also be better than only comprising with beta-schardinger dextrin-and derivant thereof the amide groups part of piracetam molecule, the latter allows heterocycle and carbonyl expose, and medicine easily produces qualitative change.Like this because above-mentioned two kinds of synergism that comprise make the piracetam molecule keep stable when pharmaceutical preparation manufacturing, storage, use.
(3) owing to improved crude drug purity, guaranteed that piracetam is high pure degree crude drug, adopted the collaborative simultaneously piracetam molecule that comprises of alpha-cyclodextrin and beta-schardinger dextrin-again, make the piracetam medicine in making, store, using, keep high stability, thereby make drug dose keep high stability, reduced impurity of the drug content like this, thereby reduce untoward reaction of medicine own and side effect, strengthened medicine and in human body, discharged stability, created conditions for keeping medicine to stablize curative effect.
(4), make medicine slighter, because glutathion protects the liver, kidney reaches antiradiation drug toxic action in Liver and kidney to human liver, the slight toxic action of kidney in the adding of reductive glutathione.
(4) the present invention makes the piracetam medicine have better social benefit for people provide more effective, safer piracetam formulation.
Therefore, it has the advantage that curative effect of medication is good, stability is strong, the untoward reaction side effect is little and safety is good.
Clinical efficacy
(1) piracetam compositions of the present invention is to neurosurgery coma patient consciousness recovery effect observation of curative effect
The treatment back is average before the treatment improves
GCS scoring GCS scoring mark
Piracetam composition injection 6.7 ± 2.1 13.6 ± 2.2 6.9
The smooth one pack system injection 7.9 in west, pyrrole position ± 3.5 11.9 ± 4.7 4.0
(2) piracetam combination treatment oligophrenia observation of curative effect of the present invention
The effective number total effective rate of case sum produce effects number
Piracetam composition injection 30 5 (18%) 17 (56%) 74%
Piracetam one pack system injection 30 4 (13%) 14 (48%) 61%
(3) side effect that causes of invention piracetam compositions is observed
The uncomfortable number side reaction of the nauseating number vomiting of case sum number liver rate
Piracetam composition injection 30 1 (3.5%) 1 (3.5%) 1 (2.9%) 9.9%
Piracetam one pack system injection 30 2 (6.5%) 2 (6.5%) 2 (6.7%) 20.8%
The specific embodiment
Embodiment one
1, the small-volume injection compositions is divided and content
Piracetam 1000g
Reduced glutathion 600g
Sodium chloride (injection is used) 45g
Water for injection adds to 5000ml
1000 small-volume injections of packing
2, small-volume injection preparation method
(1) piracetam 1000g is dissolved in the 1000ml water for injection, adds the injection water while stirring until just dissolving is complete;
(2) dissolve good alpha-cyclodextrin, beta-schardinger dextrin-with 1000ml, while stirring the piracetam saturated solution is added in above-mentioned alpha-cyclodextrin, the beta-schardinger dextrin-solution, after adding, restir 3.5 hours;
(3) add and to have sterilized and to have stirred through 15% sodium chloride solution of activated carbon decolorizing;
(4) medicinal liquid adds the sterilized water for injection standardize solution behind 0.45 μ m and 0.22 μ m two-stage membrane filtration, surveys pyrrole and draws west load content qualified, carries out fill, with 1000 of peace berkelium packing, seals simultaneously;
(5) through 121 ℃/25min steam sterilization, lamp inspection, up-to-standard back packing, warehouse-in.
Embodiment two
1, amount injection composition component and content
Piracetam 10000g
Reduced glutathion 6000g
Sodium chloride (injection is used) 900g
Water for injection adds to 10000ml
1000 bottles of packing
2, high capacity injection preparation method
(1)～(5) step is with embodiment one small-volume injection preparation method, and difference is the adjustment of fill amount and ampule sealing is changed into the pressure butyl rubber plug and bundle is moulded aluminium lid.
Embodiment three
1, dry powder injection composition component and content
Piracetam 1000g
Reduced glutathion 600g
Sodium chloride (injection is used) 90g
Water for injection adds to 2000ml
1000 of packing
2, lyophilized injectable powder preparation method
(1)～(5) step is with embodiment one small-volume injection preparation method, and difference is that ampoule bottle changes 7ml cillin bottle packaging solution into every fill 2ml of fill amount, and ampule sealing changes false add plug butyl rubber plug into.
(6) in the freeze dryer drying baker in-48 ℃～30 ℃, vacuum pressure 1Pa～15Pa, lyophilization is to moisture≤2%, tamponade, Zha Gai, the qualified warehouse-in of detection.
The proportioning raw materials of the foregoing description can also be:
Piracetam 10g, 50g, 100g
Reduced glutathion 6g, 9g, 12g
Alpha-cyclodextrin and derivant thereof are 1-5 times of the smooth molal quantity of pyrrole hila
Beta-schardinger dextrin-and derivant thereof are 1-5 times of the smooth molal quantity of pyrrole hila
Sodium chloride accounts for 0.9% of solution total amount.
Claims (10)
1, a kind of piracetam pharmaceutical composition with function of promoting thinking and memory is characterized in that it contains following materials of weight proportions component:
Piracetam 10-100
Reduced glutathion 6-12
Other auxiliary material of acceptable on the pharmaceutics.
2, the piracetam pharmaceutical composition with function of promoting thinking and memory according to claim 1 is characterized in that its auxiliary material comprises alpha-cyclodextrin and derivant, beta-schardinger dextrin-and derivant thereof.
3, the piracetam pharmaceutical composition with function of promoting thinking and memory according to claim 2, it is characterized in that its auxiliary material consumption be:
Alpha-cyclodextrin and derivant thereof are 1-5 times of the smooth molal quantity of pyrrole hila
Beta-schardinger dextrin-and derivant thereof are 1-5 times of the smooth molal quantity of pyrrole hila
4, the piracetam pharmaceutical composition with function of promoting thinking and memory according to claim 1 and 2 is characterized in that described alpha-cyclodextrin and derivant thereof and beta-schardinger dextrin-and derivant thereof can replace with gamma-cyclodextrin and derivant thereof.
5, the piracetam pharmaceutical composition with function of promoting thinking and memory according to claim 4 is characterized in that its auxiliary material also comprises sodium chloride for injection.
6, the piracetam pharmaceutical composition with function of promoting thinking and memory according to claim 5, the consumption that it is characterized in that sodium chloride for injection is to account for 0.9% of solution total amount.
7, according to claim 1,2 or 3 described piracetam pharmaceutical compositions with function of promoting thinking and memory, its dosage form is small-volume injection, bulk capacity injection and lyophilized injectable powder, the water content of lyophilized injectable powder≤2%.
8, the present invention has the piracetam preparation of drug combination method of function of promoting thinking and memory, it is characterized in that comprising the following steps:
(1) piracetam is dissolved with water for injection, make saturated solution, under agitation be added drop-wise to again in the cyclodextrin aqueous solution, stir under the last lucifuge room temperature and further make piracetam cyclodextrin saturated solution.
(2) add sodium chloride solution and the reduced glutathion of handling through decolouring, stir, further this solution is filtered again.
9, the piracetam preparation of drug combination method with function of promoting thinking and memory according to claim 8 is characterized in that the mixing time of described (1) step is 3-5 hour; The filtration branch two-stage of described step (2) three times: the first order is the filter membrane of 0.45 μ m, and the second level is the filter membrane of 0.22 μ m, and be the membrane filtration with water for injection dilution back reuse 0.22 μ m the partial second time.
10, the piracetam preparation of drug combination method with function of promoting thinking and memory according to claim 9, the preparation method that it is characterized in that lyophilized injectable powder also comprises carries out lyophilization to water content≤2% with above-mentioned medicinal liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02123539 CN1186094C (en) | 2002-07-01 | 2002-07-01 | Piracetam medicine composition with function of promoting thinking and memory and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02123539 CN1186094C (en) | 2002-07-01 | 2002-07-01 | Piracetam medicine composition with function of promoting thinking and memory and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1398635A true CN1398635A (en) | 2003-02-26 |
| CN1186094C CN1186094C (en) | 2005-01-26 |
Family
ID=4745154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02123539 Expired - Fee Related CN1186094C (en) | 2002-07-01 | 2002-07-01 | Piracetam medicine composition with function of promoting thinking and memory and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1186094C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856493A (en) * | 2010-06-09 | 2010-10-13 | 白求恩医科大学制药厂二分厂 | Compound piracetam brain protein hydrolysate tablet and preparation method thereof |
| CN102008430A (en) * | 2010-12-17 | 2011-04-13 | 张家港市华菱化工机械有限公司 | Piracetam-containing oral liquid |
| CN104013585A (en) * | 2014-06-18 | 2014-09-03 | 海南通用康力制药有限公司 | Piracetam freeze-dried powder injection for injection and preparation method thereof |
| CN104083328B (en) * | 2009-01-29 | 2017-04-12 | Ucb生物制药私人有限公司 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives |
| CN113230216A (en) * | 2021-05-26 | 2021-08-10 | 海南通用康力制药有限公司 | Piracetam freeze-dried powder injection for injection and preparation method thereof |
-
2002
- 2002-07-01 CN CN 02123539 patent/CN1186094C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104083328B (en) * | 2009-01-29 | 2017-04-12 | Ucb生物制药私人有限公司 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives |
| CN101856493A (en) * | 2010-06-09 | 2010-10-13 | 白求恩医科大学制药厂二分厂 | Compound piracetam brain protein hydrolysate tablet and preparation method thereof |
| CN102008430A (en) * | 2010-12-17 | 2011-04-13 | 张家港市华菱化工机械有限公司 | Piracetam-containing oral liquid |
| CN104013585A (en) * | 2014-06-18 | 2014-09-03 | 海南通用康力制药有限公司 | Piracetam freeze-dried powder injection for injection and preparation method thereof |
| CN113230216A (en) * | 2021-05-26 | 2021-08-10 | 海南通用康力制药有限公司 | Piracetam freeze-dried powder injection for injection and preparation method thereof |
| CN113230216B (en) * | 2021-05-26 | 2023-04-07 | 海南通用康力制药有限公司 | Piracetam freeze-dried powder injection for injection and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1186094C (en) | 2005-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1686117A (en) | Application of levoornidazole in preparation of anti anaerobic bacteria infection medicine | |
| CN1686116A (en) | Levo ornidazole vein administration agent and its preparation method | |
| CN1850089A (en) | Methylprednisolone sodium succinate lyophilized composition and its preparing method | |
| CN1186094C (en) | Piracetam medicine composition with function of promoting thinking and memory and its prepn | |
| CN1650883A (en) | Jixitabing hydrochloride solution type injection agent | |
| CN1739505A (en) | L-ornidazole injection prepn | |
| CN112402371B (en) | Rudesiwei injection and preparation method thereof | |
| CN1803811A (en) | Nitro imidazole derivative, its preparation method and uses | |
| CN1820748A (en) | Levo-ornidazole freeze-dried powder injection | |
| CN1931874A (en) | Prepn process, medicine prepn and medicinal use of ginseng glycopeptide | |
| CN1830440A (en) | Metronidazule injection and its preparation method and use | |
| CN1193790C (en) | Thymosin composition injection and its prepn | |
| CN1493283A (en) | Edalavon powder for ampoul injection having good stability and its preparation method | |
| CN1843334A (en) | Method for promoting liposome encapsulation and its formulation | |
| CN1589806A (en) | Nystatin polyene macrolide liposome composition and preparation method thereof | |
| CN1839842A (en) | Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient | |
| CN1176658C (en) | Aseptic freeze-dried prostaglandin injection and its preparing method and use | |
| CN1565446A (en) | Freeze-drying fluconazole injection and its preparation method | |
| CN1526396A (en) | New prepn form of cefmenoxime hydrochloride for injection | |
| CN1555788A (en) | Thio pronine transfursion liquid and its preparation method | |
| CN1070053C (en) | Method for preparing butethanol of injection | |
| CN1568996A (en) | Freeze dried formulation of ciprofloxacin hydrochloride and its preparation method | |
| CN101073572A (en) | Medicinal composition for treating cold wet numbness and its production | |
| CN1679914A (en) | Medicinal composition of induced glutathione and ebeselen | |
| CN1554338A (en) | Sodium bisulfite andrographolide freeze drying preparation and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hunan Kangyuan Pharmacy Co., Ltd. Assignor: Cai Dehai Contract record no.: 2011430000208 Denomination of invention: Piracetam medicine composition with function of promoting thinking and memory and its prepn Granted publication date: 20050126 License type: Exclusive License Open date: 20030226 Record date: 20111008 |
|
| ASS | Succession or assignment of patent right |
Owner name: HUNAN KANGYUAN PHARMACY CO., LTD. Free format text: FORMER OWNER: CAI HAIDE Effective date: 20120306 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 330009 NANCHANG, JIANGXI PROVINCE TO: 410329 CHANGSHA, HUNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120306 Address after: 410329 No. 36, link road, A District, Liuyang biomedical industry park, Hunan Patentee after: Hunan Kangyuan Pharmacy Co., Ltd. Address before: 330009, room 11, 201 Bai Yi lane, Xiangshan South Road, Nanchang, Jiangxi Patentee before: Cai Haide |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050126 Termination date: 20140701 |
|
| EXPY | Termination of patent right or utility model |